Covance Inc.

Joseph C. Scodari , 56, was Worldwide Chairman, Pharmaceuticals Group, of Johnson & Johnson, a diversified healthcare company, and a member of Johnson & Johnson's Executive Committee from March 2005 until March 2008. From 2003 to March 2005, Mr. Scodari was Company Group Chairman of Johnson & Johnson's Biopharmaceutical Business. Mr. Scodari joined Johnson & Johnson in 1999 as President and COO of Centocor, Inc., when Johnson & Johnson acquired the company. Mr. Scodari is also a Director of Endo Pharmaceuticals. Mr. Scodari has been a member of the Covance Board since May 2008.

Robert M. Baylis has served as a director since May 2000 and is the Chairman of the Company's Finance & Risk Management Committee and a member of the Company's Nominating & Governance Committee. Mr. Baylis was Vice Chairman of CS First Boston, a position he held until 1996, and prior to his retirement was Chairman and Chief Executive Officer of CS First Boston Pacific Inc. Mr. Baylis is a director of New York Life Insurance Company, Host Marriott Corporation, Covance, Inc., and is Chairman of the Board for Gildan Activewear, Inc. He is an overseer of the University of Pennsylvania Museum and a Trustee of the Rubin Museum of Art. Mr. Baylis is a member of the Advisory Council of the Economics Department of Princeton University and is a Chartered Financial Analyst.

As Chief Operating Officer for Covance, Mr. Barr has operating responsibility for all of Covance's business units worldwide, including Early Development, Clinical Development, Central Labs, and Commercialization Services. He reports to the Chairman and Chief Executive Officer. Mr. Barr joined Covance in 2000 as Vice President and General Manager of Labs North America. In 2003, he was promoted to President, Early Development North America responsible for the company's North American preclinical and global Phase I operations. Under Barr's leadership, the Early Development North America operations has grown significantly. Prior to joining Covance, Mr. Barr was Global Vice President and General Manager of Marconi Medical Systems. He also spent 15 years at GE in a broad variety of positions of increasing responsibility. He holds an MBA from the National University in San Diego, Calif., and a B.S. in Electrical Engineering Technology from DeVry Institute of Technology in Phoenix, Ariz.

Today, more than ever before, pharmaceutical and biotechnology companies are required to demonstrate the value of their products in an increasingly competitive commercial marketplace. The use of biomarkers provides an excellent opportunity to optimize therapy selection and demonstrate a compelling value proposition to economic stakeholders. Companies that anticipate the potential economic benefits associated with the use of biomarkers improve the likelihood of demonstrating commercial value to payers and providers, and thus improve the commercial potential of their products by optimizing product utilization - getting the right therapy to the right patient at the right time - to improve the balance of risk and benefit. Whether in preclinical or Phase III, biomarkers can help increase the speed, cost, and quality of any drug development program. In early drug development, biomarkers help identify early toxicological effects. During late stage clinical trials, they help prove drug safety and efficacy, guide trial design, and support critical development decisions. As a result of their proven utility and future promise, biomarkers are being increasingly embraced by the medical, regulatory, and payor communities.

Michele A. Kennedy, 41, has been Covance's Corporate Vice President, Chief Accounting Officer and Controller since March 2007. Prior to this, Ms. Kennedy served as Assistant Controller of Covance. Ms. Kennedy has been with Covance for 12 years in positions of increasing responsibility. Prior to joining Covance, Ms. Kennedy was an audit manager with Ernst & Young.

Michelle Robinson is vice president of project management and signature client service at Covance, Inc., a Contract Research Organization (CRO). Prior to joining Covance in 2005, she spent 15 years at General Electric as a seasoned executive who developed and managed several high performance work teams, mainly in the health care industry. She is a new Board member, having joined in the spring of 2007.

Edgar H. Adams, Sc.D., and Jeffrey J. Stoddard, M.D., attended the Food and Drug Administration's (FDA) public hearing on the use of medication guides to communicate drug risk information to patients, Washington, D.C., June 12-13, 2007. http://www.fda.gov/cder/meeting/medication_guides_200706.htm

Helene Kennedy will present "Building Adherence by Bridging the Payment Gap for the Growing Underinsured Population" at IIR's THE Pharmaceutical Marketing Event, Philadelphia, PA, September 19-21, 2007. Sean Kennedy will present "Sequential Adaptive Considerations in Registry Application Selection" at CBI's Registries and Post-Approval Studies Congress, Philadelphia, PA, September 27-28, 2007.

Kathleen G. Bang, 59, was the President and Chief Executive Officer of Northwestern Memorial Foundation, a not-for-profit affiliate of Northwestern Memorial HealthCare ("Northwestern"), an academic medical center, from February 2002 until her retirement in 2004. Prior to February 2002, Ms. Bang was the Executive Vice President and Chief Operating Officer of Northwestern. Ms. Bang joined Northwestern in 1986 and was Executive Vice President and Chief Operating Officer since 1988. Ms. Bang also was Chair of the Governing Council for Metropolitan Hospitals of the American Hospital Association from January 1996 to December 1998, and Board member of the Illinois Hospital Association from 1995 through 2003 and served as Chair in 2002. Ms. Bang has been a member of the Covance Board since 1998.

Luis Gutierrez presented a statement at the Agency for Healthcare Research and Quality's (AHRQ) and the Food and Drug Administration's (FDA) Implementation of Risk Minimization Action Plans (RiskMAPs) to Support Quality Use of Pharmaceuticals: Opportunities and Challenges public workshop, Rockville, MD, June 25-26, 2007. http://www.fda.gov/cder/meeting/riskMAPs.htm

Dr. Moore has over 15 years experience providing R&D laboratory services to pharmaceutical and related industries. She has spent the last 10 years leading formulations, methods development, validation, and stability programs in support of drug development and manufacture. She has a proven track record of effectively managing contract research services throughout her tenure at Cook Imaging (formerly a subsidiary of Cook Pharmaceuticals), Oread Inc., Proceutics, Inc., and Covance Inc. She was most recently employed at Shire Laboratories in Rockville, Maryland. Dr. Moore received her Ph.D. in Chemistry from the University of Waterloo, Ontario, Canada.

Sandra L. Helton. Sandra L. Helton has been Executive Vice President and Chief Financial Officer of TDS for more than five years. Ms. Helton is also a member of the board of directors of TDS and TDS Telecom. Ms. Helton is a director of The Principal Financial Group, a global financial institution, and Covance, Inc., a drug development services company.

Former Chief Executive Officer of Reliant Pharmaceuticals, Inc. Former President, U.S. Human Health, Merck & Co., Inc. Dr. Sheares served as Chief Executive Officer of Reliant Pharmaceuticals, Inc., a pharmaceutical company with integrated sales, marketing and development expertise that marketed a portfolio of branded cardiovascular pharmaceutical products, from January 2007 through its acquisition by GlaxoSmithKline plc in December 2007. Prior to joining Reliant, Dr. Sheares served as President of U.S. Human Health, Merck & Co. from March of 2001 until July 2006. Prior to that time, he served as Vice President, Hospital Marketing and Sales for Merck’s U.S. Human Health business. Dr. Sheares joined Merck in 1987 as a research fellow in the Merck Research Laboratories and held a wide range of positions within Merck, in business development, sales, and marketing, before becoming Vice President in 1996. He is also a director of The Progressive Corporation and Covance Inc. Director since 2004 Age: 52

Gary E. Costley, PhD is founder and Managing Director of C & G Capital and Management LLC, a private equity company started in 2004 that invests in start-up medical technology and service companies. He was Chairman and Chief Executive Officer of International Multifoods Corporation, a manufacturer and marketer of branded consumer food and foodservice products in North America, from 1997-2004. He also serves as a director of Accelrys, a firm specializing in technology-based products and services that improve and accelerate drug discovery and chemical development; Prestige Brands a company that sells and markets a portfolio of leading OTC, household products and personal care brands; and The Principal Financial Group, a financial services company.

Randy MacDonald joined IBM in 2000 as senior vice president, Human Resources. In this position he is responsible for the global human resources practices, policies and operations of the organization and reports to Chairman, President, and Chief Executive Officer Sam Palmisano. Prior to joining IBM, Mr. MacDonald was the executive vice president of Human Resources and Administration for GTE (now Verizon Communications). Mr. MacDonald was with GTE for 17 years, holding positions of increasing responsibility. Before joining GTE, he held human resources positions at Ingersoll-Rand Company and Sterling Drug, Inc. For his contributions to the HR practice throughout his career, including HR-related research and education, Mr. MacDonald received the first Distinguished Human Resource Executive Award from the Academy of Management in 2004. In 2008, Mr. MacDonald was named Human Resource Executive Magazine's “HR Executive of the Year.” He is a member and past chair of Cornell University's Center for Advanced Human Resources Study and a past chair of the Personnel Roundtable. He is also a member of the HR Policy Association, which he serves as Chairman of its Board of Directors. In 1998, Mr. MacDonald was named a Fellow of the National Academy of Human Resources, the human resource profession's highest honor for outstanding achievement. He was elected to the Academy's Board of Directors in 2000 and serves as its Vice Chair. He also was a member of the President’s Advisory Commission on Consumer Protection and Quality in the Health Care Industry. Mr. MacDonald has a bachelor's degree in political science and a master's degree in industrial relations from St. Francis University and is a member of its Board of Trustees; he received the St. Francis University Distinguished Alumni in Business Award in 1999. Mr. MacDonald also serves as a Trustee of Bucknell University. He also is a former member of the Board of Directors of Covance.

Dr. Robert L. Barchi , who serves on our Board, has been President of Thomas Jefferson University since 2004. He served as a director for VWR from May 2006 until the company was acquired in June 2007 by affiliates of Madison Dearborn Partners, LLC. Prior to his current position at Thomas Jefferson University, Dr. Barchi was Provost of the University of Pennsylvania, having served in various capacities for more than 30 years. He was the Chair of the University's Department of Neurology and was founding Chair of its Department of Neuroscience. Dr. Barchi also served as the Director of the Mahoney Institute of Neurological Sciences for more than 12 years. In addition to his clinical and administrative responsibilities, Dr. Barchi has published extensively in the field of ion channel research, and has been elected to membership in the Institute of Medicine of the National Academy of Sciences. Dr. Barchi has been a member of the Board of Covance, Inc., a contract research organization, since October 2003 and is a trustee of Ursinus College. Dr. Barchi received bachelor and master of science degrees from Georgetown University, as well as doctor of philosophy and doctor of medicine degrees from the University of Pennsylvania.